HK Stock Movement | XUANZHUBIO-B (02575) Rises Nearly 3% as Self-Developed Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time

Stock News12-10

XUANZHUBIO-B (02575) rose nearly 3%, reaching a 1.98% increase at the time of writing, trading at HK$66.95 with a turnover of HK$15.20 million.

On December 8, the company announced that its self-developed innovative drug, Palbociclib Tablets (brand name: Xuan Yuening®), has been included for the first time in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025 Edition). The 2025 NRDL will officially take effect on January 1, 2026.

The successful inclusion in the NRDL is expected to enhance the affordability and accessibility of Xuan Yuening® for patients, facilitating broader market promotion and sales expansion. This development is anticipated to have a positive long-term impact on the company's operations.

XUANZHUBIO-B stated that it will actively support the implementation of the reimbursement policy, continue advancing hospital access, expand core markets, and increase coverage to improve patient access to the medication.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175287814?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-10 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175287814","market":"hk","top_or_hot":-1,"title":"HK Stock Movement | XUANZHUBIO-B (02575) Rises Nearly 3% as Self-Developed Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time","media":"Stock News","content":"<p>XUANZHUBIO-B (02575) rose nearly 3%, reaching a 1.98% increase at the time of writing, trading at HK$66.95 with a turnover of HK$15.20 million.</p>\n<p>On December 8, the company announced that its self-developed innovative drug, Palbociclib Tablets (brand name: Xuan Yuening®), has been included for the first time in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025 Edition). The 2025 NRDL will officially take effect on January 1, 2026.</p>\n<p>The successful inclusion in the NRDL is expected to enhance the affordability and accessibility of Xuan Yuening® for patients, facilitating broader market promotion and sales expansion. This development is anticipated to have a positive long-term impact on the company's operations.</p>\n<p>XUANZHUBIO-B stated that it will actively support the implementation of the reimbursement policy, continue advancing hospital access, expand core markets, and increase coverage to improve patient access to the medication.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | XUANZHUBIO-B (02575) Rises Nearly 3% as Self-Developed Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | XUANZHUBIO-B (02575) Rises Nearly 3% as Self-Developed Innovative Drug Xuan Yuening® Included in 2025 National Reimbursement Drug List for the First Time\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-10 13:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>XUANZHUBIO-B (02575) rose nearly 3%, reaching a 1.98% increase at the time of writing, trading at HK$66.95 with a turnover of HK$15.20 million.</p>\n<p>On December 8, the company announced that its self-developed innovative drug, Palbociclib Tablets (brand name: Xuan Yuening®), has been included for the first time in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025 Edition). The 2025 NRDL will officially take effect on January 1, 2026.</p>\n<p>The successful inclusion in the NRDL is expected to enhance the affordability and accessibility of Xuan Yuening® for patients, facilitating broader market promotion and sales expansion. This development is anticipated to have a positive long-term impact on the company's operations.</p>\n<p>XUANZHUBIO-B stated that it will actively support the implementation of the reimbursement policy, continue advancing hospital access, expand core markets, and increase coverage to improve patient access to the medication.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159992","symbol_name":"创新药","start_time":0,"source_url":"","article_id":"1175287814","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175287814","pubTimestamp":1765345632,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"XUANZHUBIO-B (02575) rose nearly 3%, reaching a 1.98% increase at the time of writing, trading at HK$66.95 with a turnover of HK$15.20 million. On December 8, the company announced that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","06978":"永泰生物-B","02575":"轩竹生物-B","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股"},"translate_title":"港股动向|轩竹生物-B(02575)涨近3%自研创新药轩悦宁®首次纳入2025年国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"02575":1,"06978":1},"content_text":"XUANZHUBIO-B (02575) rose nearly 3%, reaching a 1.98% increase at the time of writing, trading at HK$66.95 with a turnover of HK$15.20 million.\nOn December 8, the company announced that its self-developed innovative drug, Palbociclib Tablets (brand name: Xuan Yuening®), has been included for the first time in the National Reimbursement Drug List (NRDL) for Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance (2025 Edition). The 2025 NRDL will officially take effect on January 1, 2026.\nThe successful inclusion in the NRDL is expected to enhance the affordability and accessibility of Xuan Yuening® for patients, facilitating broader market promotion and sales expansion. This development is anticipated to have a positive long-term impact on the company's operations.\nXUANZHUBIO-B stated that it will actively support the implementation of the reimbursement policy, continue advancing hospital access, expand core markets, and increase coverage to improve patient access to the medication.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175287814","isCrawlerRequest":true}